Skip to main content

Table 1 Baseline characteristics of the participants that were followed up through delivery (N = 206)

From: Superiority trial of intermittent treatment with dihydroartemisinin–piperaquine versus sulfadoxine–pyrimethamine for the prevention of malaria during pregnancy

Variables

Trial groups

SP

n = 94

DP

n = 112

Mean age (years)a

27.7 ± 6.1

27.3 ± 5.7

Age-group (years), n (%)b

  

17–25

35 (37.2)

50 (44.6)

26–33

43 (46.7)

43 (38.4)

> 33

16 (17.1)

19 (17.0)

Mean gestational age in weeksa

17.7 ± 1.7

17.4 ± 1.6

Gestation age in weeks, n (%)b

  

16–17

54 (57.4)

72 (64.3)

18–20

40 (42.6)

40 (35.7)

Gravidity, n (%)b

  

Primigravidae

33 (35.1)

38 (33.9)

Multigravidae

61 (64.9)

74 (66.1)

Mean weight (kg)a

65.8 ± 14.8

63.6 ± 13.8

Mean height (m)a

1.59 ± 0.07

1.59 ± 0.08

BMI (kg/m2), n (%)b

  

< 18.5

6 (6.4)

10 (9.0)

18.5–24.9

40 (42.6)

52 (46.4)

> 24.9

48 (51.0)

50 (44.6)

Mean hemoglobin (g/dL)a

10.3 ± 1.4

10.4 ± 1.4

Anemia, n (%)b

41 (43.6)

43 (38.4)

Mean ALT level (IU/L)a

11.5 ± 6.9

12.0 ± 7.9

Elevated ALT level (> 36 IU/L), n (%)cc

1 (1.1)

3 (2.7)

  1. ALT Alanine aminotransferase
  2. aIndependent samples t test
  3. bChi-square test
  4. cFisher's exact test